Myasthenia Gravis as an Adverse Effect of Immune Checkpoint Inhibitors: A Case Report

Rivera VS, Núñez Pérez IJ and Brenes NJ
 

University of Costa Rica, Costa Rica

^*Correspondance to: Natalia Jiménez Brenes 

 PDF  Full Text Case Report | Open Access

Abstract:

Immune Checkpoint Inhibitors (ICI) are valuable therapeutic agents that enable targeted oncological treatment by interfering with key evasion mechanisms used by cancer cells. However, this therapy, by inducing a T-cell-mediated immune response disinhibition, can potentially trigger a cascade of immune toxicity with a wide range of manifestations affecting multiple systems. Myasthenia Gravis (MG) as an adverse effect of immune checkpoint inhibitors has a reported incidence of approximately 0.24%. Despite its low incidence, when it occurs as an immune-mediated adverse effect, it carries a high mortality rate, emphasizing the importance of the early recognition of its manifestations. We present a case of a 68-year-old male who developed de novo myasthenic syndrome as a secondary adverse effect of anti-PD-L1 therapy, specifically Atezolizumab.

Keywords:

Immune checkpoint inhibitors; PD-1; PD-L1; CTLA-4; Atezolizumab; Myasthenia gravis

Cite the Article:

Rivera VS, Núñez Pérez IJ, Brenes NJ. Myasthenia Gravis as an Adverse Effect of Immune Checkpoint Inhibitors: A Case Report. Clin Case Rep Int. 2023; 7: 1592.